Thanks NS. I listened a couple of times. I am not a legal expert but am wondering if there is a scenario where it’s gets remanded and Hikma is forced to specify the indication in their marketing material but not face any retroactive monetary damages. My other thought is even if it gets added to their website and other marketing material, whether Dr.’s will actually pay attention to the new wording. Without any reps visiting Dr.’s, it’s hard to educate the physicians.
Bigger picture, for me personally everything positive that may happen in the US is a welcome and somewhat unforeseen upside. oUSA and especially EU market is big enough to warrant an attractive valuation…eventually. You need the patience of Job , which I have and I suspect most of the well informed posters here do as well.
Again, all jjust my opinion.
Have a great weekend.
Market Data 
Markets 
AI
